Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer's disease
(AD), and its accumulation has been considered as the molecular driver of Alzheimer's …

Alzheimer's disease (AD) is the most common type of dementia, and no disease-modifying
treatments are available to halt or slow its progression. Amyloid-beta (Aβ) is suggested to …

Clearing amyloid-β (Aβ) through immunotherapy is one of the most promising therapeutic
approaches to Alzheimer's disease (AD). Although several monoclonal antibodies against …

Vascular dementia (VaD) constitutes the second most prevalent cause of dementia in the
world after Alzheimer's disease (AD). VaD regroups heterogeneous neurological conditions …

Carnosine (β-alanyl-L-histidine) is a naturally occurring endogenous peptide widely
distributed in excitable tissues such as the brain. This dipeptide has well-known antioxidant …

Immunotherapy directed against tau is a promising treatment strategy for Alzheimer's
Disease (AD) and tauopathies. We review initial studies on tau-directed immunotherapy …

The deposition of amyloid β peptide (Aβ) is one of the main pathological features of AD. The
much-talked sensory gamma entrainment may be a new treatment for Aβ load. Here we …

Monocytes play a crucial role in Alzheimer's disease (AD), and docosahexaenoic acid
(DHA) has a neuroprotective effect for many neurodegenerative diseases. However …

The role of myeloid cells (granulocytes and monocytes) in neurodegeneration and
neurodegenerative disorders (NDD) is indisputable. Here we discuss the roles of myeloid …

Aging societies have high incidence rates of Alzheimer's disease (AD). AD is diagnosed at
later disease stages and has a poor prognosis, and effective drugs and treatments for AD …